JAK2 and breast cancer: We use T47D and TMX2-28 breast cancer cells stably overexpressing GFP, PAK1 WT, or tyrosyl phosphorylation-deficient mutant of PAK1 in which the three JAK2 phosphorylation sites have been mutated to phenylalanine (PAK1 Y3F).